Finance

A pedestrian walks past the Alibaba headquarters building in Beijing.
Sheldon Cooper/SOPA Images | LightRocket | Getty Images

Shares of Chinese companies listed publicly in the U.S. surged Wednesday as China on Wednesday signaled support for the stocks.

Regulators from both countries are progressing toward a cooperation plan on U.S.-listed Chinese stocks, according to Chinese state media. The report cited a meeting Wednesday chaired by Vice Premier Liu He, who heads China’s finance committee.

The Chinese government supports the listing of companies overseas and said its crackdown on technology companies should end soon, the state media report said.

Alibaba jumped about 20%, JD.com added 24% and Pinduoduo rallied more than 35% in the premarket Wednesday.

U.S.-listed Chinese stocks

The move comes as American depositary receipts of Chinese companies have been beaten down recently amid regulatory and delisting fears. ADRs are shares of non-U.S. firms traded on U.S. exchanges.

The Nasdaq Golden Dragon China index, which tracks the performance of U.S.-listed Chinese stocks, is down 38.8% in 2022 and 69.2% in the past 12 months.

The Securities and Exchange Commission last week named five U.S.-listed ADRs of Chinese companies that failed to comply with the Holding Foreign Companies Accountable Act.

The act allows the SEC to delist and even ban companies from listing on U.S. exchanges if American regulators cannot review company audits for three consecutive years.

Last summer, Chinese regulators stepped up their oversight on U.S.-listed Chinese stocks. Regulators reportedly asked Chinese ride-hailing giant Didi to delist from the U.S. months after the company’s IPO.

— CNBC’s Evelyn Cheng contributed to this report.

Articles You May Like

Activist Jana Partners calls for a strategic review at Wolfspeed. Here’s how it may develop
Exxon stock falls as earnings miss on lower natural gas prices and squeezed refining margins
Open seating no more? Southwest CEO says airline is weighing cabin changes
Nvidia supplier SK Hynix reverses losses in first quarter on explosive AI demand
FTC challenges ‘junk’ patents held by 10 drugmakers, including for Novo Nordisk’s Ozempic